Source: International Congress 2018 – Improving the outcomes of community-acquired pneumonia
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
D. Basille (Amiens, France), R. Thomsen (Aarhus, Denmark), M. Madsen (Aarhus, Denmark), P. Duhaut (Amiens, France), C. Andrejak (Amiens, France), V. Jounieaux (Amiens, France), H. SøRensen (Aarhus, Denmark). Non-steroidal anti-inflammatory drug use and clinical outcomes of community-acquired pneumonia. 2024

Member's Comments

No comment yet.

Related content which might interest you: Nonsteroidal anti-inflammatory drugs in community-acquired pneumonia Source: Eur Respir J 2015; 46: 876-877 Year: 2015 Nonsteroidal anti-inflammatory drugs in community-acquired pneumonia Source: Eur Respir J 2015; 46: 875-876 Year: 2015 Non-steroidal anti-inflammatory drugs may worsen the course of community-acquired pneumonia : A cohort study Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Influence of prior nonsteroidal anti-inflammatory steroidal drugs (NSAID) on the presentation and evolution of hospitalized community-acquired pneumonia Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Macrolides as anti-inflammatory agents in CAP Source: Eur Respir Monogr 2014; 63: 243-255 Year: 2014 Active monitoring of adverse drug reactions to the use of beta-lactam antibiotics in the treatment of community-acquired pneumonia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020 A randomized trial of AZD7594 a novel non-steroidal anti-inflammatory drug in asthma patients Source: International Congress 2017 – Novel mechanisms and treatments for asthma Year: 2017 Macrolides, mucoactive drugs and adherence for the management of bronchiectasis Source: Eur Respir J, 51 (1) 1702033; 10.1183/13993003.02033-2017 Year: 2018 Macrolides, mucoactive drugs and adherence for the management of bronchiectasis Source: Eur Respir J, 51 (1) 1701987; 10.1183/13993003.01987-2017 Year: 2018 Inhaled drugs as risk factors for community-acquired pneumonia Source: Eur Respir J 2010; 36: 1080-1087 Year: 2010 Inhaled drugs as risk factors for community-acquired pneumonia Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools Year: 2010 Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia Source: Eur Respir J, 50 (3) 1602306; 10.1183/13993003.02306-2016 Year: 2017 Update on anti-inflammatory therapy in asthma Source: Research Seminar 2012 - Pulmonary inflammation in paediatric respiratory disease Year: 2012 Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007 Antipyretic effect of dexamethasone in community-acquired pneumonia Source: Eur Respir J 2015; 46: 570-573 Year: 2015 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 The etiology and antimicrobial drugs resistance of microorganisms in patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 2s Year: 2006 Whether there are pharmacoeconomic and other advantages of using procalcitonin-guide antibacterial treatment in patients with severe community-acquired pneumonia in developing countries? Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia Source: Eur Respir J 2011; 37: 1332-1339 Year: 2011